SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
President Donald Trump holds a news conference about the ongoing global coronavirus pandemic in the Rose garden at the White House March 13, 2020 in Washington, D.C. (Photo: Drew Angerer/Getty Images)
'Depraved': Trump Reportedly Offered German Firm 'Large Sum' for Exclusive Rights to Coronavirus Vaccine
"Trump wanted not only to control any new vaccine but also to make sure that it would only be available on a for-profit basis."
Mar 16, 2020
German lawmakers and government officials voiced outrage at reporting Sunday that the Trump administration is seeking to secure exclusive rights to a potential coronavirus vaccine being developed by the German firm CureVac as the pandemic spreads and takes lives across the globe.
The German newspaper Welt am Sonntag, citing an anonymous German government official, reported Sunday that the Trump administration offered CureVac $1 billion to hand the U.S. exclusive rights to a potential COVID-19 vaccine.
Trump wants the vaccine "only for the USA," the German official said. The New York Times confirmed late Sunday that the Trump administration attempted to persuade CureVac to move its research to the U.S., offering the company what one German official described as a "large sum" of money.
"Germany is not for sale," economy minister Peter Altmaier declared in response to the bombshell reporting, which White House officials said was overblown.
"International cooperation is important now, not national self-interest," said conservative lawmaker Erwin Rueddel, a member of the German parliament's health committee.
Led by Chancellor Angela Merkel, German government ministers on Monday are planning to convene a crisis meeting that will include discussion of CureVac, which is headquartered in Tubingen, Germany but also has an office in Boston, Massachusetts.
"Top White House aides were unaware of any communication by or offer from President Trump to CureVac," the Washington Post reported, citing an anonymous administration official. "The official cautioned, however, that Trump often has private conversations of which his staff is not aware, and therefore the official could not definitively rule out that any such discussion had occurred."
The Trump administration has faced backlash for refusing to vow that any COVID-19 vaccine will be affordable for all in the U.S.--let alone free, as progressives and public health experts are demanding.
"We would want to ensure that we'd work to make it affordable, but we can't control that price because we need the private sector to invest," U.S. Health and Human Services Secretary Alex Azar said during a congressional hearing last month.
Reuters reported Sunday that CureVac has "started with a multitude of coronavirus vaccine candidates and was now selecting the two best to go into clinical trials."
"The privately-held company... hopes to have an experimental vaccine ready by June or July to then seek the go-ahead from regulators for testing on humans," Reuters noted.
Christof Hettich, chief executive of Dievini Hopp Biotech Holding, CureVac's main investor, told the German newspaper Mannheimer Morgen on Sunday that it has no plans to allow any nation to purchase exclusive rights to a potential COVID-19 vaccine.
"We want to develop a vaccine for the whole world, and not for individual countries," said Hettich.
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
German lawmakers and government officials voiced outrage at reporting Sunday that the Trump administration is seeking to secure exclusive rights to a potential coronavirus vaccine being developed by the German firm CureVac as the pandemic spreads and takes lives across the globe.
The German newspaper Welt am Sonntag, citing an anonymous German government official, reported Sunday that the Trump administration offered CureVac $1 billion to hand the U.S. exclusive rights to a potential COVID-19 vaccine.
Trump wants the vaccine "only for the USA," the German official said. The New York Times confirmed late Sunday that the Trump administration attempted to persuade CureVac to move its research to the U.S., offering the company what one German official described as a "large sum" of money.
"Germany is not for sale," economy minister Peter Altmaier declared in response to the bombshell reporting, which White House officials said was overblown.
"International cooperation is important now, not national self-interest," said conservative lawmaker Erwin Rueddel, a member of the German parliament's health committee.
Led by Chancellor Angela Merkel, German government ministers on Monday are planning to convene a crisis meeting that will include discussion of CureVac, which is headquartered in Tubingen, Germany but also has an office in Boston, Massachusetts.
"Top White House aides were unaware of any communication by or offer from President Trump to CureVac," the Washington Post reported, citing an anonymous administration official. "The official cautioned, however, that Trump often has private conversations of which his staff is not aware, and therefore the official could not definitively rule out that any such discussion had occurred."
The Trump administration has faced backlash for refusing to vow that any COVID-19 vaccine will be affordable for all in the U.S.--let alone free, as progressives and public health experts are demanding.
"We would want to ensure that we'd work to make it affordable, but we can't control that price because we need the private sector to invest," U.S. Health and Human Services Secretary Alex Azar said during a congressional hearing last month.
Reuters reported Sunday that CureVac has "started with a multitude of coronavirus vaccine candidates and was now selecting the two best to go into clinical trials."
"The privately-held company... hopes to have an experimental vaccine ready by June or July to then seek the go-ahead from regulators for testing on humans," Reuters noted.
Christof Hettich, chief executive of Dievini Hopp Biotech Holding, CureVac's main investor, told the German newspaper Mannheimer Morgen on Sunday that it has no plans to allow any nation to purchase exclusive rights to a potential COVID-19 vaccine.
"We want to develop a vaccine for the whole world, and not for individual countries," said Hettich.
German lawmakers and government officials voiced outrage at reporting Sunday that the Trump administration is seeking to secure exclusive rights to a potential coronavirus vaccine being developed by the German firm CureVac as the pandemic spreads and takes lives across the globe.
The German newspaper Welt am Sonntag, citing an anonymous German government official, reported Sunday that the Trump administration offered CureVac $1 billion to hand the U.S. exclusive rights to a potential COVID-19 vaccine.
Trump wants the vaccine "only for the USA," the German official said. The New York Times confirmed late Sunday that the Trump administration attempted to persuade CureVac to move its research to the U.S., offering the company what one German official described as a "large sum" of money.
"Germany is not for sale," economy minister Peter Altmaier declared in response to the bombshell reporting, which White House officials said was overblown.
"International cooperation is important now, not national self-interest," said conservative lawmaker Erwin Rueddel, a member of the German parliament's health committee.
Led by Chancellor Angela Merkel, German government ministers on Monday are planning to convene a crisis meeting that will include discussion of CureVac, which is headquartered in Tubingen, Germany but also has an office in Boston, Massachusetts.
"Top White House aides were unaware of any communication by or offer from President Trump to CureVac," the Washington Post reported, citing an anonymous administration official. "The official cautioned, however, that Trump often has private conversations of which his staff is not aware, and therefore the official could not definitively rule out that any such discussion had occurred."
The Trump administration has faced backlash for refusing to vow that any COVID-19 vaccine will be affordable for all in the U.S.--let alone free, as progressives and public health experts are demanding.
"We would want to ensure that we'd work to make it affordable, but we can't control that price because we need the private sector to invest," U.S. Health and Human Services Secretary Alex Azar said during a congressional hearing last month.
Reuters reported Sunday that CureVac has "started with a multitude of coronavirus vaccine candidates and was now selecting the two best to go into clinical trials."
"The privately-held company... hopes to have an experimental vaccine ready by June or July to then seek the go-ahead from regulators for testing on humans," Reuters noted.
Christof Hettich, chief executive of Dievini Hopp Biotech Holding, CureVac's main investor, told the German newspaper Mannheimer Morgen on Sunday that it has no plans to allow any nation to purchase exclusive rights to a potential COVID-19 vaccine.
"We want to develop a vaccine for the whole world, and not for individual countries," said Hettich.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.